Biocon and Mylan to Present Final Overall Survival Data for OgivriTM(trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting

  • Posted by: Biocon Biologics

Biocon Q4FY19 Revenue Rs 1,557 Cr, Up 26%; EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr FY19 Revenue Up 31% at Rs 5,659 Cr; Net Profit Up 143% at Rs 905 Cr

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Conferred With Honorary Doctorate from Deakin University, Australia

  • Posted by: Biocon Biologics

Biocon Facility Completes Pre Approval U.S. FDA Inspection

  • Posted by: Biocon Biologics

Biocon Appoints Dr. Christiane Hamacher as CEO Of Biocon Biologics India Limited

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw elected as Member of the National Academy of Engineering, U.S.

  • Posted by: Biocon Biologics

Biocon Q3FY19 Earnings Revenue at Rs 1,566 Cr, Up 43%; Net Profit at Rs 217 Cr, Up 136% EBITDA at Rs 406 Cr, Up 59%

  • Posted by: Biocon Biologics

Biosimilar Trastuzumab Co-Developed by Biocon Receives Approval in the EU

  • Posted by: Biocon Biologics

Biocon Foundation Dedicates Rejuvenated Hebbagodi Lake and Children’s Park to the Community

  • Posted by: Biocon Biologics

Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU

  • Posted by: Biocon Biologics
Share